Geneious Biologics’ powerful cloud computing platform quickly and accurately analyzes NGS data, helping you better understand the diversity and quality of your antibody libraries and immune repertoires. Engineered to intelligently manage and process NGS data, Geneious Biologics provides intuitive visualization tools that accelerate identification of therapeutic antibody candidates. Geneious Biologics brings together advanced analytics tools in a user friendly interface to improve accuracy and increase success in therapeutic antibody discovery.
- Analyze millions of NGS raw antibody sequences in minutes
- QC/trim, assemble, merge paired end data
- Preview, annotate and compare NGS sequences with no manual intervention
- Automatically validate sequences – define your own rules
- Search and filter on large NGS datasets
- Cluster and index annotated NGS sequences
- Show cluster diversity and region length plots
- Compare NGS data sets and plot results of germline, diversity and region frequency
- Inspect individual sequences in large data sets using the intuitive sequence viewer
- Identify outliers, see cluster and sequence distribution with scatter plots
- Visualize interesting clusters and sequences with sequence viewer
- Look at amino acid variability with (aa) composition plots
- Show relationships between genes in sequences with heat map graphs
- Leverage versatile stack bar charts/histogram capability to quickly understand trends
- Spot high-level trends in large scale antibody NGS datasets
- Drill down into individual sequences
- Achieve deep understanding of your antibody data
- Accelerate precision antibody discovery
Often you have to shoehorn a software solution into your process, the adaptability of Geneious Biologics was something we liked a lot. Once we knew what we could do with Geneious Biologics there was no other viable option.
We have been very pleased with the quality of the software, as well as with the interaction with Biomatters’ staff who have proven to be very responsive to technical questions and suggestions for further development.
Companies of our size and nature appreciate working with companies of the same mindset. The advantage with Geneious Biologics is – it is scientists talking to scientists.
One of the remaining bottlenecks to efficiently identify optimal antibody candidates is antibody sequence processing. Providing insight into large antibody sequence and data sets, such as can be retrieved from Isogenica’s fully synthetic human Fab or llamdA VHH domain antibody libraries, will speed up biologic drug development.
Geneious Biologics will allow our licensees to optimally use the data on the large number of leads retrieved from our libraries and, ultimately, enhance biologic drug development processes.
We are evolving from a cottage industry to an industrialized process, part of our challenge is ensuring our data maintains integrity and consistency with that evolution. We need software that can work with our unique Bicycle® platform and take our data quality to the next level.
New technologies like Geneious Biologics will play an important role in allowing researchers to better leverage existing molecular data sets.
Working with Geneious Biologics to apply this application to the analysis of our unique data sets has been enabling for Bicycle Therapeutics and I can see how this could drastically improve speed and accuracy in other areas of drug development.
Geneious Biologics allows us to drill into huge antibody sequence sets and quickly identify where errors lie and inspect bad clones. This will ensure we return the most effective, stable therapeutic antibody candidates to our clients, faster.
We are incorporating more high-throughput sequencing into our core business, and are screening increasingly large quantities of unique and complex VHH-based multi-specific biologics. Geneious Biologics will help us scale-up our screening efforts.